Home \ Antibodies \ SIRL-1, Human, mAb 1A5
Catalog # HM2309

SIRL-1, Human, mAb 1A5

Please choose the quantity of items you wish to add to your cart…
Find distributor

The monoclonal antibody 1A5 recognizes human Signal inhibitory Receptor on Leucocytes-1 (SIRL-1). In order to prevent host tissue damage immune activation has to be tighly regulated. Neutrophils and other myeloid cells have a pivotal role in controlling infection. They form the primary response at site of infection as they regulate replication of pathogens by phagocytosis, secretion of antimicrobial peptides and proinflammatory cytokines to activate the immune system. Without regulation these mediators can cause tissue damage or worse. To balance the immune response immune cells can express inhibitory receptors.
The family of immune inhibitory receptors is still expending. The relatively new receptor SIRL-1 is an immunoreceptor tyrosine-based inhibitory motif (ITIM)-bearing membrane protein expressed on human phagocytes. SIRL-1 contains two ITIMs in the intracellular tail, which are crucial for function. SIRL-1 can recruit the SH2-domain containing tyrosine phosphatases, SHP-1 and SHP-2, which may mediate the inhibitory effect. ITIM-bearing receptors inhibit signals relayed by immunoreceptor tyrosine-based activating motifs (ITAMs). ITAMs are the principal mediators of signal transduction for various receptors, including FcRs and C-type lectins.
The ligation of SIRL-1 dampens Fc receptor induced ROS production in phagocytes, thereby impairing the microbicidal activity of neutrophils without affecting phagocytosis. Infectious stimuli cause rapid downregulation of SIRL-1 expression. This allows microbial killing and clearance of pathogens.
Neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). Using anti SIRL-1 antibodies both spontaneous anti-neutrophil antibody induced NET formation is suppressed. This suggests a regulatory role for SIRL-1 in NET formation and a therapeutic target for regulation of SLE.

Application
Flow cytometry, Functional studies, Immuno precipitation, Western blot

Application Notes
W: A non-reduced sample treatment and SDS-Page was used. The band sizes are 45 kDa and fainter band of 37 kDa in transfected cells and 37 kDa in granulocytes (Ref.1). FS: Antibody 1A5 showed inhibition of FcεRI-mediated degranulation by RBL-2H3 cells transfected with SIRL-1. The percentage of inhibition of degranulation by SIRL-1 was calculated by (OD405 TNP stimulation – OD405 TNP with SIRL-1 crosslinking)/(OD405 TNP stimulation – OD405 spontaneous release) x 100.

Use
For immuno precipitation, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
Amount
100 µg, 20 µg
Formulation
0.2 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.
Immunogen
Purified SIRL-1-hIg fusion protein in PBS
Isotype
Mouse IgG1
Species
Human
Alias
V-set and transmembrane domain-containing protein 1, Signal inhibitory receptor on leukocytes-1
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease
Autoimmunity, Infectious diseases
CoA-TDS HM2300-HM2400 Safety Data Sheet

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us